Stugeron® can cause drowsiness, especially at the beginning of the course of treatment, so you should refrain from drinking alcohol and take care when sharing with drugs that depress the central nervous system.
In connection with the presence of antihistamine effect, cinnarizine can affect the result of the anti-doping control of athletes (false positive result), and can also neutralize positive reactions in conducting skin diagnostic tests (4 days before the study treatment should be canceled).
With long-term use of the drug, a control examination of the liver, kidney function, and clinical analysis of peripheral blood is recommended. Patients suffering from Parkinson's disease, cinnarizine should be assigned only in cases where the benefits from his appointment exceed the possible risk of deterioration.
Patients with such rare hereditary disorders as galactose intolerance, lactase deficiency or glucose / galactose malabsorption syndrome should not be taken cinnarizine, since the preparation contains 175 mg of lactose monohydrate.